Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial

S. Hong, David; A. Van Tine, Brian; Biswas, Swethajit; McAlpine, Cheryl; L. Johnson, Melissa; J. Olszanski, Anthony; Clarke, Jeffrey; M. Araujo, Dejka; R. Blumenschein, George; Kebriaei, Partow; Lin, Quan; J. Tipping, Alex; P. Sanderson, Joseph; Wang, Ruoxi; Trivedi, Trupti; Annareddy, Thejo; P. F. Bai, Jane; Rafail, Stavros; Sun, Amy; Fernandes, Lilliam; Navenot, Jean‐Marc; D. Bushman, Frederic; Everett, J.K.; F. Karadeniz, Derin; Broad, Robyn; Isabelle, Martin; Naidoo, Revashnee; Bath, Natalie; Betts, Gareth; Wolchinsky, Zohar; G. Batrakou, Dzmitry; Van Winkle, Erin; Elefant, Erica; Ghobadi, Armin; F. Cashen, Amanda; Grand’Maison, Anne; L. McCarthy, Philip; M. Fracasso, Paula; Norry, Elliot; Williams, Dennis; Druta, Mihaela; A. Liebner, David; Odunsi, Kunle; O. Butler, Marcus

doi:10.1038/s41591-022-02128-z

Public

Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial

Published in Nature Medicine • Jan 1, 2023

Authors:

David S. Hong

Brian A. Van Tine

Swethajit Biswas

Abstract

Affinity-optimized T cell receptors can enhance the potency of adoptive T cell therapy. Afamitresgene autoleucel (afami-cel) is a human leukocyte antigen-restricted autologous T cell therapy targeting melanoma-associated antigen A4 (MAGE-A4), a cancer/testis antigen expressed at varying levels in mu...

Subject

Medicine

Internal medicine

Oncology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!